IQVIA Named Leader in IDC MarketScape’s 2024 Decentralized Clinical Trial Assessment

IQVIA Named Leader in IDC MarketScape’s 2024 Decentralized Clinical Trial Assessment

IQVIA Recognized as a Leader in IDC MarketScape’s 2024 Assessment for Decentralized Clinical Trial Technologies and Consulting Services IQVIA, a global leader in AI-powered analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, has been…

Read MoreIQVIA Named Leader in IDC MarketScape’s 2024 Decentralized Clinical Trial Assessment
Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease

Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease

Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced that the first patient has been dosed in its Phase 2a clinical trial evaluating VENT-02 in patients with…

Read MoreVentus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease
Noramco Invests $25M in Halo Pharma’s Whippany Facility for Sterile Injectables

Noramco Invests $25M in Halo Pharma’s Whippany Facility for Sterile Injectables

Noramco Group Announces $25 Million Investment in Halo Pharma’s Whippany Facility for Sterile Injectable Manufacturing The Noramco Group, a prominent North American provider of integrated Active Pharmaceutical Ingredient (API) and drug product supply chain services, has made a strategic $25…

Read MoreNoramco Invests $25M in Halo Pharma’s Whippany Facility for Sterile Injectables
Ionis Pharmaceuticals, Inc. has announced that its partnership with AstraZeneca has led to the approval of WAINZUA (eplontersen) by the European Union (EU)

WAINZUA (eplontersen) EU-Approved for Stage 1/2 Hereditary Transthyretin-Mediated Amyloido

Ionis Pharmaceuticals, Inc. has announced that its partnership with AstraZeneca has led to the approval of WAINZUA (eplontersen) by the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy.…

Read MoreWAINZUA (eplontersen) EU-Approved for Stage 1/2 Hereditary Transthyretin-Mediated Amyloido